Log in

NASDAQ:CLSDClearside Biomedical Stock Price, Forecast & News

$1.85
-0.01 (-0.54 %)
(As of 06/2/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.85
Now: $1.85
$1.95
50-Day Range
$1.74
MA: $1.99
$2.41
52-Week Range
$0.56
Now: $1.85
$4.13
Volume224,900 shs
Average Volume800,391 shs
Market Capitalization$83.01 million
P/E RatioN/A
Dividend YieldN/A
Beta1.07
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Read More
Clearside Biomedical logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLSD
CUSIPN/A
Phone678-270-3631

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.17 million
Book Value$0.25 per share

Profitability

Net Income$-30,770,000.00
Net Margins-293.61%

Miscellaneous

Employees50
Market Cap$83.01 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive CLSD News and Ratings via Email

Sign-up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter.

Clearside Biomedical (NASDAQ:CLSD) Frequently Asked Questions

How has Clearside Biomedical's stock been impacted by COVID-19 (Coronavirus)?

Clearside Biomedical's stock was trading at $2.59 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CLSD shares have decreased by 28.6% and is now trading at $1.85. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Clearside Biomedical?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Clearside Biomedical.

When is Clearside Biomedical's next earnings date?

Clearside Biomedical is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Clearside Biomedical.

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical Inc (NASDAQ:CLSD) issued its quarterly earnings results on Friday, May, 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.11) by $0.04. The business had revenue of $4.10 million for the quarter, compared to analyst estimates of $4 million. Clearside Biomedical had a negative net margin of 293.61% and a negative return on equity of 165.19%. View Clearside Biomedical's earnings history.

What price target have analysts set for CLSD?

5 equities research analysts have issued 1-year price objectives for Clearside Biomedical's stock. Their forecasts range from $4.00 to $8.00. On average, they expect Clearside Biomedical's stock price to reach $6.00 in the next year. This suggests a possible upside of 224.3% from the stock's current price. View analysts' price targets for Clearside Biomedical.

Has Clearside Biomedical been receiving favorable news coverage?

Media coverage about CLSD stock has trended very negative this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Clearside Biomedical earned a media sentiment score of -3.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutClearside Biomedical.

Are investors shorting Clearside Biomedical?

Clearside Biomedical saw a decline in short interest in May. As of May 15th, there was short interest totaling 1,500,000 shares, a decline of 10.2% from the April 30th total of 1,670,000 shares. Based on an average trading volume of 524,900 shares, the days-to-cover ratio is currently 2.9 days. Approximately 4.5% of the company's stock are short sold. View Clearside Biomedical's Current Options Chain.

Who are some of Clearside Biomedical's key competitors?

What other stocks do shareholders of Clearside Biomedical own?

Who are Clearside Biomedical's key executives?

Clearside Biomedical's management team includes the following people:
  • Dr. George M. Lasezkay Pharma.D., J.D., Interim CEO & Director (Age 67)
  • Mr. Charles A. Deignan, Chief Financial Officer (Age 55)
  • Mr. Stephen C. Kilmer, Investor Relations Officer (Age 53)
  • Mr. Leslie B. Zacks, Gen. Counsel, Chief Compliance Officer & Sec. (Age 50)
  • Mr. Rick McElheny, VP of Corp. Devel.

When did Clearside Biomedical IPO?

(CLSD) raised $50 million in an initial public offering (IPO) on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

What is Clearside Biomedical's stock symbol?

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

Who are Clearside Biomedical's major shareholders?

Clearside Biomedical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Carmignac Gestion (4.41%), BlackRock Inc. (1.69%), Geode Capital Management LLC (0.73%), Morgan Stanley (0.58%), Signaturefd LLC (0.27%) and Oxford Financial Group Ltd. (0.20%). Company insiders that own Clearside Biomedical stock include Charles A Deignan, Clay Thorp, Daniel H White, George M Lasezkay and Nancy J Hutson. View institutional ownership trends for Clearside Biomedical.

Which major investors are selling Clearside Biomedical stock?

CLSD stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., and UBS Group AG. View insider buying and selling activity for Clearside Biomedical.

Which major investors are buying Clearside Biomedical stock?

CLSD stock was bought by a variety of institutional investors in the last quarter, including Carmignac Gestion, Morgan Stanley, Oxford Financial Group Ltd., Signaturefd LLC, Geode Capital Management LLC, Jane Street Group LLC, Fred Alger Management LLC, and BlackRock Inc.. Company insiders that have bought Clearside Biomedical stock in the last two years include Charles A Deignan, Clay Thorp, Daniel H White, George M Lasezkay, and Nancy J Hutson. View insider buying and selling activity for Clearside Biomedical.

How do I buy shares of Clearside Biomedical?

Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Clearside Biomedical's stock price today?

One share of CLSD stock can currently be purchased for approximately $1.85.

How big of a company is Clearside Biomedical?

Clearside Biomedical has a market capitalization of $83.01 million and generates $2.17 million in revenue each year. The company earns $-30,770,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Clearside Biomedical employs 50 workers across the globe.

What is Clearside Biomedical's official website?

The official website for Clearside Biomedical is www.clearsidebio.com.

How can I contact Clearside Biomedical?

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.